Jennifer S. Buell: Too Many Patients Face Unbearable Downstream Burdens That We Simply Can’t Ignore
Jennifer S. Buell, President and Chief Executive Officer at MiNK Therapeutics, shared Agenus’s post on LinkedIn:
“At MiNK Therapeutics, we are adding some of the most impactful cells, iNKT cells, to ICIs in a Phase 2 trial in GI cancers – because too many patients face unbearable downstream burdens that we simply can’t ignore.
Cancer is ‘systemic’ and it impacts far more than just the body – it disrupts daily life, work, and the dynamics within a family. As Dr. Ben Schlechter of Dana‑Farber Cancer Institute puts it: ‘Young adults with cancer – at the end of their life, there is a much longer tail of suffering and care that they need… and we believe that immune therapy can, in a subset of individuals, limit that.’
At MiNK Therapeutics and Agenus, our mission is to translate that promise into reality – harnessing iNKT cells alone and in active combination not only to extend survival, but to meaningfully reduce the long‑term physical, emotional, and financial toll on patients and their loved ones.”
Quoting Agenus’s post:
“Colon cancer impacts far more than just the body – it disrupts daily life, work, and the dynamics within a family.
In the video below, Dana-Farber Cancer Institute ’s lead researcher Dr. Ben Schlechter shares insight into the true burden colon cancer places on patients and their loved ones.
For additional information and resources, please visit our patient and care partners page.”
More posts featuring Jennifer S. Buell.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023